Article
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer.
Genomics - 1 Jul 2017
O'Shannessy Daniel J, Bendas Katie, Schweizer Charles, Wang Wenquan, Albone Earl, Somers Elizabeth B, Weil Susan, Meredith Rhonda K, Wustner Jason, Grasso Luigi, Landers Mark, Nicolaides Nicholas C
Abstract excerpt
Farletuzumab (FAR) is a humanized monoclonal antibody (mAb) that binds to folate receptor alpha. A Ph3 trial in ovarian cancer patients treated with carboplatin/taxane plus FAR or placebo did not meet the primary statistical endpoint. Subgroup analysis demonstrated that subjects with high FAR exposure levels (Cmin>57.6μg/mL) showed statistically significant improvements in PFS and OS. The neonatal Fc receptor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.